# Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

> **NCT02974933** · PHASE2 · UNKNOWN · sponsor: **Wuling Ou** · enrollment: 48 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib combined with pemetrexed

## Key facts

- **NCT ID:** NCT02974933
- **Lead sponsor:** Wuling Ou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-11
- **Final completion:** 2018-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2017-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974933, "Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02974933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*